- Study finds fourfold increase in OxyContin prescriptions dispensed near U.S.-Canada border tunnel
- FDA approves Actavis drug for opioid dependence
- NCPA among industry associations rejecting proposal to reschedule hydrocodone
- Actavis can launch generic OxyContin in January 2014 under settlement with Purdue
- FDA approves Amneal opioid-dependence drug
PARSIPPANY, N.J. — Actavis and Mallinckrodt have reached a settlement concerning the former's generic version of an opioid painkiller made by the latter, Actavis said Thursday.
The companies settled patent lawsuit regarding Actavis' generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride) extended-release tablets in the 32-mg strength. The companies settled litigation regarding the 8-mg, 12-mg and 16-mg strengths last month.
Under the settlement, Mallinckrodt granted Actavis a loyalty-free license to its U.S. patents on Exalgo, allowing Actavis to start selling the 32-mg strength in generic form starting in May 2014. Actavis said it was likely the first company to file for Food and Drug Administration approval of a generic version of the drug, which would entitle it to 180 days in which to compete exclusively against the branded version after approval.